Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Gladstone, Douglas E  [Clear All Filters]
2022
Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, et al. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022;12(12):165.
2021
Sterling CH, Tsai H-L, Holdhoff M, Bolaños-Meade J, Luznik L, Fuchs EJ, Huff CAnn, Gocke CB, Ali SAbbas, Borrello IM, et al. "Allogeneic blood or marrow transplant with non-myeloablative conditioning and high dose cyclophosphamide-based graft-versus-host disease prophylaxis for secondary central nervous system lymphoma". Transplant Cell Ther. 2021.
2020
DeZern AE, Zahurak ML, Symons HJ, Cooke KR, Rosner GL, Gladstone DE, Huff CAnn, Swinnen LJ, Imus P, Borrello I, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020;4(8):1770-1779.
Lally K, Kruse RL, Smetana H, Davis R, Roots A, Marshall C, Ness PM, DeZern AE, Gladstone DE, Brennan DC, et al. Isohemagglutinin titering performed on an automated solid-phase and hemagglutinin-based analyzer is comparable to results obtained by manual gel testing. Transfusion. 2020.
2019
Imus PH, Blackford AL, Bettinotti M, Luznik L, Fuchs EJ, Huff CAnn, Gladstone DE, Ambinder RF, Borrello IM, Fuchs RJ, et al. Severe cytokine release syndrome after haploidentical peripheral blood transplantation. Biol Blood Marrow Transplant. 2019.